Stockscreener 앱 받기
9.10
0.55%
-0.05
CorMedix Inc 주식(CRMD)의 최신 뉴스
CorMedix Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Upward Trajectory: CorMedix Inc (CRMD) Posts a Gaine, Closing at 8.50 - DWinneX
CorMedix Inc (CRMD) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Perhaps timely catching CorMedix Inc (CRMD) would be a good idea - Sete News
Breakeven Is Near for CorMedix Inc. (NASDAQ:CRMD) - simplywall.st
Are CorMedix Inc’shares a good deal? - uspostnews.com
Why Buy Stock In CorMedix Inc (CRMD)? - Marketing Sentinel
(CRMD) On The My Stocks Page - news.stocktradersdaily.com
Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years - Yahoo Finance
RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term - Yahoo Finance
CorMedix expects Q1 sales above estimates, lifts H1 outlook - MSN
CorMedix reports preliminary Q1 revenue $39M, consensus $32.2M. - TipRanks
CorMedix at Needham Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
CorMedix at Needham Conference: Strategic Growth and Challenges - Investing.com
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated - MSN
CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and Raises H1 Guidance, But Will the Momentum Continue? - RagingBull
CorMedix Inc. Raises Financial Guidance for First Half of 2025 - marketscreener.com
CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance - MarketScreener
CorMedix reports strong preliminary Q1 revenue and EBITDA By Investing.com - Investing.com India
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance - The Manila Times
CorMedix Logs Q1 Prel. Revenue Of $39 Mln - Nasdaq
CorMedix reports strong preliminary Q1 revenue and EBITDA - Investing.com
CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
CorMedix CEO Sets Stage for Strategic Updates at Elite Needham Healthcare Conference - Stock Titan
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks
CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance
CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN
CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire
The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com
Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada
CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia
CorMedix: Q4 Earnings Snapshot - MySA
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com
CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com
CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener
Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks
0.24%
36.06%
자본화:
|
볼륨(24시간):